MedInCell Stock Rises 4.23% to €26.14, Breaking Technical Resistance
The biotech company from Montpellier opens the trading session on Wednesday, May 6, 2026, with a strong acceleration. The MedInCell stock climbs 4.23% to €26.14 in a well-oriented Parisian market, extending its rebound from the previous day.
An Acceleration that Exceeds Technical Resistance
The price clearly surpasses its identified resistance at €25.12, after approaching it the previous day during a session that saw the stock challenge this graphical threshold. The breakout is accompanied by an overflow of the upper boundary of the Bollinger Bands at €25.78. The price now moves above this envelope, a configuration that indicates a short-term rush. The RSI at 58 remains in the neutral zone and does not send a marked overbought signal. Over seven days, the progress reaches 14.35%. The stock also moves back above its 50-day and 200-day moving averages, located at €22.92 and €24.27 respectively.
Focus on the R&D Day on May 12
The financial calendar sets the next concrete appointment in less than a week, with an R&D day scheduled live on Tuesday, May 12, 2026. The annual results for the fiscal year April 2025-March 2026 will follow on Tuesday, June 16. During the semi-annual publication covering the period April-September 2025, the company mentioned an expected acceleration of revenues in the coming years with olanzapine LAI, for which the registration dossier (NDA) has been submitted. Among the opportunities mentioned was also the revision of the 2025 sales forecasts for UZEDY® by the partner Teva, now in a range of $190 to $200 million. The annual performance is nearly 70%, with the stock having doubled its low from the beginning of the year. The May 12 meeting will provide an update on the portfolio of development programs.
